218 related articles for article (PubMed ID: 37092583)
1. IL-1β Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer.
Wang D; Cheng C; Chen X; Wang J; Liu K; Jing N; Xu P; Xi X; Sun Y; Ji Z; Zhao H; He Y; Zhang K; Du X; Dong B; Fang Y; Zhang P; Qian X; Xue W; Gao WQ; Zhu HH
Adv Sci (Weinh); 2023 Jun; 10(17):e2206889. PubMed ID: 37092583
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells.
Wang S; Huang M; Chen M; Sun Z; Jiao Y; Ye G; Pan J; Ye W; Zhao J; Zhang D
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295817
[TBL] [Abstract][Full Text] [Related]
3. IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells.
Chang MA; Patel V; Gwede M; Morgado M; Tomasevich K; Fong EL; Farach-Carson MC; Delk NA
J Cell Biochem; 2014 Dec; 115(12):2188-97. PubMed ID: 25103771
[TBL] [Abstract][Full Text] [Related]
4. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
[TBL] [Abstract][Full Text] [Related]
5. Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
Sasaki T; Yoshikawa Y; Kageyama T; Sugino Y; Kato M; Masui S; Nishikawa K; Inoue T
Prostate; 2023 Mar; 83(4):364-375. PubMed ID: 36479717
[TBL] [Abstract][Full Text] [Related]
6. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis.
Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B
J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
10. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
11. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
12. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
13. Foxa2 activates the transcription of androgen receptor target genes in castrate resistant prostatic tumors.
Connelly ZM; Yang S; Chen F; Yeh Y; Khater N; Jin R; Matusik R; Yu X
Am J Clin Exp Urol; 2018; 6(5):172-181. PubMed ID: 30510969
[TBL] [Abstract][Full Text] [Related]
14. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer.
El-Kenawi A; Dominguez-Viqueira W; Liu M; Awasthi S; Abraham-Miranda J; Keske A; Steiner KK; Noel L; Serna AN; Dhillon J; Gillies RJ; Yu X; Koomen JM; Yamoah K; Gatenby RA; Ruffell B
Cancer Res; 2021 Nov; 81(21):5477-5490. PubMed ID: 34301759
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.
Cioni B; Zaalberg A; van Beijnum JR; Melis MHM; van Burgsteden J; Muraro MJ; Hooijberg E; Peters D; Hofland I; Lubeck Y; de Jong J; Sanders J; Vivié J; van der Poel HG; de Boer JP; Griffioen AW; Zwart W; Bergman AM
Nat Commun; 2020 Sep; 11(1):4498. PubMed ID: 32908142
[TBL] [Abstract][Full Text] [Related]
16. Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.
Derderian S; Benidir T; Scarlata E; Altaylouni T; Hamel L; Zouanat FZ; Brimo F; Aprikian A; Chevalier S
J Pathol Clin Res; 2023 Jul; 9(4):285-301. PubMed ID: 37073437
[TBL] [Abstract][Full Text] [Related]
17. Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer.
Gannon PO; Godin-Ethier J; Hassler M; Delvoye N; Aversa M; Poisson AO; Péant B; Alam Fahmy M; Saad F; Lapointe R; Mes-Masson AM
PLoS One; 2010 Aug; 5(8):e12107. PubMed ID: 20711410
[TBL] [Abstract][Full Text] [Related]
18. VSSP-activated macrophages mediate senescence and tumor inhibition in a preclinical model of advanced prostate cancer.
Alvarez-Arzola R; Bancaro N; Lai P; Attanasio G; Pellegrini L; Troiani M; Colucci M; Mosole S; Pasquini E; Alimonti A; Mesa C
Cell Commun Signal; 2023 Apr; 21(1):76. PubMed ID: 37055829
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer.
Qin C; Wang J; Du Y; Xu T
Front Endocrinol (Lausanne); 2022; 13():1055826. PubMed ID: 36506053
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
Wadosky KM; Koochekpour S
Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
